Clinical effectiveness
SE, low disease
DISEASE, SECONDARY, REMISSION, REGRESSION, DISEASE
The primary outcome of sustained CDAI LDA was achieved by 36.9% vs. 40.3% of patients in the T2T vs. RC group, over the course of 12 months (Achievement of sustained Clinical Disease Activity Index (CDAI) low disease activity (LDA). Analysis of secondary endpoints demonstrated that CDAI LDA at months 3, 6, 9 and 12 was achieved by 37.7%, 47.9%, 60.9%, and 57.0% of patients in the T2T group compared with 35.5%, 43.4%, 50.4%, and 53.7% of those managed per RC, while the rates of CDAI remission at months 3–12 ranged from 8.5–22.1% in the T2T group, and 5.8–17.9% in the RC group (Fig. Achievement of secondary disease outcomes through 1 year. Logistic regression analysis of the odds of achieving secondary outcomes showed that compared with RC, patients in the T2T group were more likely to achieve CDAI LDA (OR [95% CI]: 1.33 [1.03–1.71], Survival analysis for the time to achieve secondary outcomes demonstrated that patients managed per T2T had a significantly shorter mean (SE) time to achieve SDAI remission than those treated through RC (K-M estimated: 14.0 [0.6] vs. 19.3 [0.8] months, Time to achievement of secondary disease outcomes. 